ZZZhen Zhang

Zhen Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhen Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of Potent and Selective RIPK1 Degraders with In Vivo Efficacy for Cancer Treatment

    by Zhen Zhang, Chunrong Li, Nina Hawkins, Ramesh Mudududdla, Yiming Nie, Peng-Kai Liu, Penghsuan Huang, Natalia Del Rio, Hao Chang, Matthew Brown, et al.

    Receptor-interacting protein kinase 1 (RIPK1) is a threonine/serine kinase that serves as a critical regulator of immune re-sponses and cell death pathways, functioning through both its catalytic kinase activity and non-catalytic scaffold function. The scaffold function of RIPK1 contributes to both intrinsic and extrinsic resistance to immune checkpoint blockades (ICBs), making it a compelling therapeutic target for enhancing cancer immunotherapy. Recent studies have highlighted RIPK1’s potential as a key modulator for improving the efficacy of immune-stimulatory therapies, such as ICBs and radio-therapy. In this study, we have developed a highly potent and selective RIPK1 degrader. Our degrader demonstrated signifi-cant tumor growth suppression when combined with X-ray radiotherapy (XRT), achieving enhanced therapeutic efficacy without adverse effects on body weight. These findings underscore the potential of RIPK1 degradation as a novel approach to augment radiotherapy and advance cancer immunotherapy strategies.